Aqueous humor and plasma levels of vascular endothelial growth factor and interleukin-8 in patients with central serous chorioretinopathy

Retina

Volumn 30, Issue 9, 2010, Pages 1465-1471

  Lim, Ji Won ^a   Kim, Min Uk ^a   Shin, Min Cheol ^a  

^a Hallym University   (South Korea)

Author keywords

aqueous humor; central serous chorioretinopathy; interleukin 8; plasma; vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; INTERLEUKIN 8; VASCULOTROPIN;

ADULT; AGED; AQUEOUS HUMOR; ARTICLE; CATARACT; CENTRAL SEROUS RETINOPATHY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MALE; PROTEIN BLOOD LEVEL; VISUAL ACUITY;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; AQUEOUS HUMOR; CENTRAL SEROUS CHORIORETINOPATHY; COLORING AGENTS; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INDOCYANINE GREEN; INTERLEUKIN-8; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 78049274103     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181d8e7fe     Document Type: Article

References (27)

1. Gass JD. Pathogensis of disciform detachment of neuroepi-thelium: II. Idiopathic central serous chorioretinopathy. Am J Ophthalmol 1967;63:587-615.
2. Wang M, Munch IC, Hasler PW, Priinte C, Larsen M. Central serous chorioretinopathy. Acta Ophthalmol 2008;86:126-145.
3. Torres-Soriano ME, Garcia-Aguirre G, Kon-Jara V, et al. A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (case reports). Graefes Arch Clin Exp Ophthalmol 2008;246:1235-1239.
4. Schaal KB, Hoeh AE, Scheuerle A, Schuett F, Dithmar S. Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy. Eur J Ophthalmol 2009;19:613-617.
5. Seong HK, Bae JH, Kim ES, Han JR, Nam WH, Kim HK. Intravitreal bevacizumab to treat acute central serous chori oretinopathy: short-term effect. Ophthalmologica 2009;223: 343-347.
6. Lim SJ, Roh MI, Kwon OW. Intravitreal bevacizumab injection for central serous chorioretinopathy. Retina 2010;30:100-106.
7. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizu-mab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331-335. (Pubitemid 41073112)
8. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 363-372. e5.
9. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevaci-zumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005;36:336-339. (Pubitemid 41073113)
10. Levine R, Brucker AJ, Robinson F. Long-term follow-up of idiopathic central serous chorioretinopathy by fluorescein angiography. Ophthalmology 1989;96:854-859. (Pubitemid 19165113)
11. Loo RH, Scott IU, Flynn HW Jr, et al. Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina 2002;22:19-24.
12. Burumcek E, Mudun A, Karacorlu S, Arslan MO. Laser photocoagulation for persistent central serous retinopathy: results of long-term follow-up. Ophthalmology 1997;104: 616-622. (Pubitemid 27171982)
13. Cardillo Piccolino F, Eandi CM, Ventre L, Rigault de la Longrais RC, Grignolo FM. Photodynamic therapy for chronic central serous chorioretinopathy. Retina 2003;23:752-763. (Pubitemid 38040573)
14. Chan WM, Lam DS, Lai TY, Tam BS, Liu DT, Chan CK. Choroidal vascular remodelling in central serous chorioretin-opathy after indocyanine green guided photodynamic therapy with verteporfin: A novel treatment at the primary disease level. Br J Ophthalmol 2003;87:1453-1458.
15. Colucciello M. Choroidal neovascularization complicating photody-namic therapy for central serous retinopathy. Retina 2006;26:239-242. (Pubitemid 44400737)
16. Ober MD, Eandi CM, Jampol LM, Fine HF, Yannuzzi LA. Focal retinal pigment epithelium breaks in central serous chorioretinopathy. Retin Cases Brief Rep 2007;l:271-274.
17. Yoshida A, Yoshida S, Khalil AK, Ishibashi T, Inomata H. Role of NF-kappaB-mediated interleukin-8 expression in intraocular neo-vascularization. Invest Ophthalmol Vis Sci 1998;39:1097-1106. (Pubitemid 28247343)
18. Kramer M, Goldenberg-Cohen N, Axer-Siegel R, Wein berger D, Cohen Y, Monselise Y. Inflammatory reaction in acute retinal artery occlusion: cytokine levels in aqueous humor and serum. Ocul Immunol Inflamm 2005;13:305-310. (Pubitemid 41702774)
19. Yuuki T, Kanda T, Kimura Y, et al. Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreo-retinopathy. J Diabetes Complications 2001;15:257-259. (Pubitemid 32750613)
20. Paroli MP, Teodori C, D'Alessandro M, Mariani P, Iannucci G, Paroli M. Increased vascular endothelial growth factor levels in aqueous humor and serum of patients with quiescent uveitis. Eur J Ophthalmol 2007;17:938-942. (Pubitemid 351262904)
21. Prunte C, Flammer J. Choroidal capillary and venous congestion in central serous chorioretinopathy. Am J Ophthalmol 1996;121: 26-34. (Pubitemid 26026078)
22. Spaide RF, Hall L, Haas A, et al. Indocyanine green video-angiography of older patients with central serous chorioretinopathy. Retina 1996;16:203-213. (Pubitemid 26190849)
23. Uyama M, Matsunaga H, Matsubara T, Fukushima I, Takahashi K, Nishimura T. Indocyanine green angiography and pathophysiology of multifocal posterior pigment epitheliopathy. Retina 1999;19: 12-21. (Pubitemid 30387535)
24. Petreaca ML, Yao M, Liu Y, Defea K, Martins-Green M. Transactivation of vascular endothelial growth factor receptor-2 by interleukin-8 (IL-8/CXCL8) is required for IL-8/ CXCL8-induced endothelial permeability. Mol Biol Cell 2007;18: 5014-5023. (Pubitemid 350246701)
25. Noma H, Funatsu H, Yamasaki M, et al. Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye 2008; 22:42-48.
26. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Phar-macokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007;114:855-859.
27. Bednarz J, Weich HA, Rodokanaki-von Schrenck A, En-gelmann K. Effect of differentiation on expression of genes for growth factors and growth factor receptors in human corneal endothelial cells [in German]. Ophthalmologe 1996;93:268-274